Taj Pharma is the largest generic pharmaceutical company in India. We hold top positions in different established markets worldwide generics markets..
Each tablet contains
Atorvastatin………......................................... 10 mg
Atorvastatin………......................................... 20 mg
Lipirol is a prescription drug. It is used in patients with multiple risk factors for heart disease such as family history, high blood pressure, age ,low HDL or smoking to reduce the risk of heart attack and stroke. Lipirol is also used in patients with type 2 diabetes and at least one other risk factor for heart disease such as high blood pressure, smoking or complications of diabetes, including eye disease and protein in urine, to reduce the risk of heart attack and stroke.
Atorvastatin (Lipitor) is a selective, competitive inhibitor of HMG CoA reductase, the rate-limiting enzyme that converts 3-hydroxy 3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Cholesterol and triglycerides circulate in the bloodstream as party of lipoprotein complexes. With ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), IDL (intermediate-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions.
Triglycerides (TG) and cholesterol in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily
through the high-affinity LDL receptor. Clinical and pathologic studies wshow that elevated plasma levels of total cholestero (total-C), LDL-cholesterol (LDL-C), and apolipoprotein B (apo B) promote human atherosclerosis and are risk factors for developing cardiovascular disease, while increased levels of HDL-C are associated with a decreased cardiovascular risk.
In animal models, Atorvastatin (Lipitor) lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL; Atorvastatin (Lipitor) also reduces LDL production and the number of LDL particles. Atorvastatin (Lipitor) reduces LDL-C in some patients with homozygous familial hypercholesterolemia (FH), a population that rarely responds to other lipid-lowering medication.
A variety of clinical studies have demonstrated that elevated levels of total-C, LDL-C, and apo B (a membrane complex for LDL-C) promote human atherosclerosis. Similarly, decreased levels of HDL-C (and its transport complex, apo A) are associated with the development of atherosclerosis. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C, and inversely with the level of HDL-C. Although frequently found in association with low HDL-C, elevated plasma TG has not been established as an independent risk factor for coronary heart disease. The independent effect of of raising HDL-C or lowering TG on the risk fro coronary and cardiovascular morbidity and mortality has not been established.
Atorvastatin (Lipitor) reduces total-C, LDL-C, and apo B in patients with homozygous and heterozygous FH, nonfamilial forms of hypercholesterolemia, and mixed dyslipidemia. Atorvastatin (Lipitor) also reduces VLDL-C and TG and produces variable increases in HDL-C and apolipoprotein A-1. The effect of Atorvastatin (Lipitor) on cardiovascular morbidity and mortality has not been determined. Like LDL, cholesterol-enriched triglyceride-rich lipoproteins,
including VLDL, intermediate density lipoprotein (IDL), and remnants, can also promote atherosclerosis. Elevated plasma triglycerides are frequently found in a triad with low HDL-C levels and small LDL particles, as well as in association with non-lipid metabolic risk factors for coronary heart disease. As such, total plasma TG has not consistently been shown to be an
independent risk factor for CHD. Furthermore, the independent effect of raising HDL or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.
As per the physician’s advice.